Skip to main content

Research Repository

Advanced Search

All Outputs (37)

A novel biosensor for prediction of global hypomethylation by decitabine and azacytadine in leukaemic cells (2015)
Journal Article
May, J. E., Allainguillaume, J., Page, K., Stratford-Smith, C., Aruomaren, A., Alloush, H., …Anderson, E. (2015). A novel biosensor for prediction of global hypomethylation by decitabine and azacytadine in leukaemic cells. Mutagenesis, 30(6), 856. https://doi.org/10.1093/mutage/gev074

Decitabine (DAC) and azacytidine (AZA) are cytidine ana- logues and hypomethylating agents used in the manage- ment of patients with myelodysplastic syndrome (MDS), where the main goal is to prevent transformation to acute myeloid leukaemia (AML), wh... Read More about A novel biosensor for prediction of global hypomethylation by decitabine and azacytadine in leukaemic cells.

Chemotherapy-induced cytotoxicity and genotoxicity to the bone marrow microenvironment (2013)
Journal Article
May, J. E., Morse, H. R., Page, K., Soh, M., Wexler, S., Cox, C., …Donaldson, C. (2014). Chemotherapy-induced cytotoxicity and genotoxicity to the bone marrow microenvironment. Mutagenesis, 29(1), 79. https://doi.org/10.1093/mutage/get060

The bone marrow (BM) microenvironment is largely com- prised of mesenchymal stromal cells (MSCs) and is vital in supporting haematopoiesis. Limited studies have indicated that the BM microenvironment is damaged by chemotherapy; however the extent and... Read More about Chemotherapy-induced cytotoxicity and genotoxicity to the bone marrow microenvironment.

Effects of bone marrow stromal cells on sensitivity of leukaemic cells to chemotherapy (2013)
Journal Article
Page, K., Anderson, E., Smith, A., Reid, C., Salisbury, V., Donaldson, C., & May, J. E. (2014). Effects of bone marrow stromal cells on sensitivity of leukaemic cells to chemotherapy. Mutagenesis, 29(1), 92. https://doi.org/10.1093/mutage/get060

Cytosine arabinoside (ara-C) is a key chemotherapy drug used to treat acute myeloid leukaemia (AML), however, ap- proximately 30% of patients do not respond to this therapy. 92 An evaluative assay to determine resistance/sensitivity to ara- C prior... Read More about Effects of bone marrow stromal cells on sensitivity of leukaemic cells to chemotherapy.

Use of whole blood for analysis of disease-associated biomarkers (2013)
Journal Article
McLeod, J., Pemberton, R. M., May, J. E., Pemberton, R., Hart, J. P., McLeod, J. D., …Doran, O. (2013). Use of whole blood for analysis of disease-associated biomarkers. Analytical Biochemistry, 437(1), 59-61. https://doi.org/10.1016/j.ab.2013.02.024

Analyses for diagnosis and monitoring of pathological conditions often rely on blood samples, partly due to relative ease of collection. However, many interfering substances largely preclude the use of whole blood itself, necessitating separation of... Read More about Use of whole blood for analysis of disease-associated biomarkers.

Multiple myeloma: The bone marrow microenvironment and its relation to treatment (2013)
Journal Article
Andrews, S. W., Kabrah, S., May, J. E., Donaldson, C., & Morse, H. R. (2013). Multiple myeloma: The bone marrow microenvironment and its relation to treatment. British Journal of Biomedical Science, 70(3), 110-120. https://doi.org/10.1080/09674845.2013.11669945

Multiple myeloma is the most common haematological malignancy yet currently it remains incurable. For decades the mainstay in therapy has been non-targeted approaches including genotoxic agents and immunosuppressants. With myeloma predominantly affec... Read More about Multiple myeloma: The bone marrow microenvironment and its relation to treatment.

Development of a novel, physiologically relevant cytotoxicity model: Application to the study of chemotherapeutic damage to mesenchymal stromal cells (2012)
Journal Article
May, J. E., Morse, H. R., Xu, J., & Donaldson, C. (2012). Development of a novel, physiologically relevant cytotoxicity model: Application to the study of chemotherapeutic damage to mesenchymal stromal cells. Toxicology and Applied Pharmacology, 263(3), 374-389. https://doi.org/10.1016/j.taap.2012.07.013

There is an increasing need for development of physiologically relevant in-vitro models for testing toxicity, however determining toxic effects of agents which undergo extensive hepatic metabolism can be particularly challenging. If a source of such... Read More about Development of a novel, physiologically relevant cytotoxicity model: Application to the study of chemotherapeutic damage to mesenchymal stromal cells.

Chemotherapy-induced damage to mesenchymal stem cells: An in vitro model (2011)
Presentation / Conference
May, J. E., Morse, R., Xu, J., Avent, N. D., Febrey, S., Cox, C., …Donaldson, C. (2011, November). Chemotherapy-induced damage to mesenchymal stem cells: An in vitro model. Poster presented at In Vitro Toxicology Society Annual Meeting, Liverpool, UK

An in vitro model of chemotherapeutic damage to mesenchymal stem cells (2010)
Presentation / Conference
May, J. E., Xu, J., Morse, R., Avent, N. D., Cox, C., Wexler, S. A., & Donaldson, C. (2010, April). An in vitro model of chemotherapeutic damage to mesenchymal stem cells. Poster presented at 4th UK Mesenchymal Stem Cell Meeting, Leeds University, UK

Chemotherapeutic damage to mesenchymal stem cells (2010)
Presentation / Conference
May, J. E., & Donaldson, C. (2010, March). Chemotherapeutic damage to mesenchymal stem cells. Poster presented at SET for Britain Event 2010, House of Commons, London, UK

Mesenchymal stem cell response to chemotherapeutic damage (2009)
Presentation / Conference
May, J. E., Xu, J., Morse, R., Avent, N. D., Cox, C., Wexler, S. A., & Donaldson, C. (2009, March). Mesenchymal stem cell response to chemotherapeutic damage. Paper presented at 35th Annual meeting EBMT and 25th Meeting of the Nurses Group, Goteborg, Sweden

Toxicity testing: The search for an in vitro alternative to animal testing (2009)
Journal Article
May, J. E., Xu, J., Morse, R., Avent, N. D., & Donaldson, C. (2009). Toxicity testing: The search for an in vitro alternative to animal testing. British Journal of Biomedical Science, 66(3), 160-165. https://doi.org/10.1080/09674845.2009.11730265

Prior to introduction to the clinic, pharmaceuticals must undergo rigorous toxicity testing to ensure their safety. Traditionally, this has been achieved using in vivo animal models. However, besides ethical reasons, there is a continual drive to red... Read More about Toxicity testing: The search for an in vitro alternative to animal testing.